pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Vizz
drug
save

aceclidine

Marketedupdated 6mo ago
by $LENZ LENZ Therapeutics, Inc.
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying aceclidine

  • phase3Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopiacompletedn=300
  • phase3Phase 3 Safety Study for the Treatment of Presbyopia Subjectscompletedn=362
  • phase1Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopiacompletedn=21
  • phase1Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopiacompletedn=30

Patent cliff

source: FDA Orange Book
first barrier falls
Jul 31, 2030
~3.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (6)

  • Mar 15, 2044method-of-use (U-3741)US 12414942
  • Oct 8, 2039method-of-use (U-3741)US 12128036
  • Oct 8, 2039method-of-use (U-3741)US 12533347
  • Mar 24, 2034formulationUS 10052313
  • Mar 24, 2034method-of-use (U-3741)US 11179328
  • Mar 24, 2034formulationUS 9844537

FDA exclusivities (1)

  • Jul 31, 2030NCENew Chemical Entity (5y)3.7y

News(1)

  • Biopharma layoffs rise YOY in October but sharply trend down for 2026
    October marked the first time this year there was an increase in both the number of biotech and pharma companies trimming their workforces and the number of affected employees when compared to 2025…
    biospace · 5d ago
brand
Vizz
generic
aceclidine
indication
Presbyopia
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?